10. April 2017

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Matter-Walstra K, Schwenkglenks M, Dedes KJ. Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer...